Zhejiang Hisun Pharmaceutical (600267.SH): Evomoside tablets obtained drug registration certificate.

Zhejiang Hisun Pharmaceutical (600267.SH) announced that the company recently received the "Drug Registration Certificate" for Everolimus Tablets issued by the National Medical Products Administration (referred to as the "NMPA"). It is reported that Everolimus is indicated for adult patients with advanced renal cell carcinoma who have previously failed treatment with sunitinib or sorafenib; adult patients with unresectable, locally advanced or metastatic, well-differentiated (moderately or highly differentiated) pancreatic neuroendocrine tumors; adult patients with unresectable, locally advanced or metastatic, well-differentiated, progressive non-functional gastrointestinal or lung origin neuroendocrine tumors (NET); adult and pediatric patients with subependymal giant cell astrocytoma (SEGA) related to tuberous sclerosis complex (TSC) who require therapeutic intervention but are not suitable for surgical resection; adult patients with renal angiomyolipoma (TSC-AML) related to tuberous sclerosis complex (TSC) who do not require immediate surgical treatment; and postmenopausal women with hormone receptor-positive, epidermal growth factor receptor-2 negative, advanced breast cancer who have failed treatment with aromatase inhibitors or fulvestrant, when used in combination with exemestane.